Blood analyte sensing using fluorescent dye-loaded red blood cells

Measurement of blood analytes provides crucial information about a patient’s health. Some such analytes, such as glucose in the case of diabetes, require long-term or near-continuous monitoring for proper disease management. However, current monitoring techniques are far from ideal: multiple-per-day finger stick tests are inconvenient and painful for the patient; implantable sensors have short functional life spans (i.e., 3-7 days). Due to analyte transporters on red blood cell (RBC) membranes that equilibrate intracellular and extracellular analyte levels, RBCs serve as an attractive alternative for encapsulating analyte sensors. Once reintroduced to the blood stream, the functionalized RBCs may continue to live for the remainder of their life span (120 days for humans). They are biodegradable and biocompatible, thereby eliminating the immune system response common for many implanted devices. The proposed sensing system utilizes the ability of the RBCs to swell in response to a decrease in the osmolarity of the extracellular solution. Just before lysis, they develop small pores on the scale of tens of nanometers. While at low temperature, analyte-sensitive dyes in the extracellular solution diffuse into the perforated RBCs and become entrapped upon restoration of temperature and osmolarity. Since the fluorescent signal from the entrapped dye reports on changes in the analyte level of the extracellular solution via the RBC transporters, interactions between the RBCs and the dye are critical to the efficacy of this technique. In this work, we study the use of a near infrared pH sensitive dye encapsulated within RBCs and assess the ability to measure dye fluorescence in vivo.

[1]  Julie Wagner,et al.  Invasiveness as a barrier to self-monitoring of blood glucose in diabetes. , 2005, Diabetes technology & therapeutics.

[2]  M. S. Kirkman,et al.  Response to Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61 , 2011, Diabetes Care.

[3]  L. Machesky,et al.  Fluorescent erythrocyte ghosts as standards for quantitative flow cytometry. , 1995, Cytometry.

[4]  F. Kuypers,et al.  Effect of osmotic lysis and resealing on red cell structure and function. , 1990, The Journal of laboratory and clinical medicine.

[5]  R. Flower,et al.  Observation of erythrocyte dynamics in the retinal capillaries and choriocapillaris using ICG-loaded erythrocyte ghost cells. , 2008, Investigative ophthalmology & visual science.

[6]  Bruce Buckingham,et al.  Toward closing the loop: an update on insulin pumps and continuous glucose monitoring systems. , 2010, Endocrinology and metabolism clinics of North America.

[7]  V. Basevi Standards of Medical Care in Diabetes—2011 , 2011, Diabetes Care.

[8]  J. M. Lanao,et al.  Drug, enzyme and peptide delivery using erythrocytes as carriers. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[9]  S. Ritter,et al.  Encapsulation of FITC to monitor extracellular pH: a step towards the development of red blood cells as circulating blood analyte biosensors , 2011, Biomedical optics express.

[10]  M. Lieber,et al.  Dynamics of the holes in human erythrocyte membrane ghosts. , 1982, The Journal of biological chemistry.

[11]  M. Magnani,et al.  Erythrocyte-based drug delivery , 2005, Expert opinion on drug delivery.

[12]  J. Tobias,et al.  Continuous pH Monitoring Using the Paratrend® 7 Inserted into a Peripheral Vein in a Patient with Shock and Congenital Lactic Acidosis , 2002, Clinical pediatrics.

[13]  Mehrdad Hamidi,et al.  Carrier Erythrocytes: An Overview , 2003, Drug delivery.

[14]  N. Marsden,et al.  Accumulation of Dextran in Human Red Cells after Hæmolysis , 1959, Nature.

[15]  A. Carruthers,et al.  Facilitated diffusion of glucose. , 1990, Physiological reviews.

[16]  Mehrdad Hamidi,et al.  Applications of carrier erythrocytes in delivery of biopharmaceuticals. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[17]  Mark R. Burge,et al.  Continuous Glucose Monitoring: The Future of Diabetes Management , 2008 .

[18]  R H Glew,et al.  Enzyme loading of erythrocytes. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D. Williamson,et al.  Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence , 2010, Population health metrics.

[20]  P. Lefevre EVIDENCE OF ACTIVE TRANSFER OF CERTAIN NON-ELECTROLYTES ACROSS THE HUMAN RED CELL MEMBRANE , 1948, The Journal of general physiology.

[21]  M. Abdel-Kader,et al.  Mammalian erythrocytes as physiological carriers of fluorescent exogenous agents: a comparative study of bovine and camel red blood cells. , 1995, Artificial organs.

[22]  G. Mcgarraugh The chemistry of commercial continuous glucose monitors. , 2009, Diabetes technology & therapeutics.